SCHEMBL562257

SCHEMBL562257

CCCCOc1nc(NCc2ccc(OC)cc2)c([N+](=O)[O-])c(N)c1Cc1ccc(OC)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.49
NPSR1 Q6W5P4 2/20 0.49
EGFR P00533 1/20 0.49
NPC1 O15118 3/20 0.47
HTT P42858 3/20 0.46
GAA P10253 1/20 0.46
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA7 P43166 1/20 0.43
CA13 Q8N1Q1 1/20 0.43
MAPK1 P28482 1/20 0.43
RECQL P46063 1/20 0.43
BLM P54132 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
RAB9A P51151 1/20 0.43
KMT2A Q03164 1/20 0.43
LMNA P02545 2/20 0.41
HPGD P15428 1/20 0.41
ALDH1A1 P00352 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27713967 0.86 ALDH1A1 (0.45) MAPTNPSR1NPC1RAB9AKMT2A
SCHEMBL563543 0.86 MAPT (0.48) MAPTNPSR1EGFRNPC1HTT
SCHEMBL563184 0.83 EGFR (0.53) MAPTNPSR1EGFRNPC1HTT
SCHEMBL25379641 0.77 MAPT (0.64) MAPTNPSR1EGFRNPC1HTT
SCHEMBL24615269 0.73 NPC1 (0.54) MAPTNPSR1EGFRNPC1HTT
SCHEMBL31266407 0.73 NPC1 (0.54) MAPTNPSR1EGFRNPC1HTT
SCHEMBL563562 0.72 ALDH1A1 (0.54) NPSR1HTTMAPK1L3MBTL1LMNA
SCHEMBL10506512 0.72 EGFR (0.57) MAPTNPSR1EGFRNPC1HTT
SCHEMBL562853 0.72 EGFR (0.46) MAPTNPSR1EGFRNPC1HTT
SCHEMBL563105 0.72 EGFR (0.54) MAPTNPSR1EGFRNPC1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120035209-A1 Hydroxy Substituted 1H-Imidazopyridines and Methods PFIZER INC. (US) 2012-02-09 US disclosed
US-20100152230-A1 HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS PFIZER INC. 2010-06-17 US disclosed
EP-1924581-A1 HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS Pfizer, Inc. (US) 2008-05-28 EP disclosed
WO-2007028129-A1 HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS PFIZER INC. (US) 2007-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152230-A1 HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS IL4, IL2, IL4I1 MAPT 4506/4885NPSR1 3082/4885EGFR 3495/4885
US-20120035209-A1 Hydroxy Substituted 1H-Imidazopyridines and Methods IL2, IL4, IL4I1 MAPT 4506/4885NPSR1 3304/4885EGFR 3412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.